Basic Information
| LncRNA/CircRNA Name | DLEU1 |
| Synonyms | NA |
| Region | GRCh38_13:50082171-50723236 |
| Ensemble | ENSG00000176124 |
| Refseq | NR_002605 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay, RIP |
| Sample | Human astrocyte cell line (NHA) and four glioma cell lines (U87, U251, LN229 and A172), glioma tissues and matched adjacent brain tissues |
| Expression Pattern | up-regulated |
| Function Description | The results revealed that DLEU1 was significantly upregulated in glioma tissues and cell lines. Increased DLEU1 was positively associated with the high-grade carcinoma (III-IV). Functional studies revealed that knockdown of DLEU1 expression by siRNA led to decreased proliferation, migration and invasion and increased apoptosis in human glioma cells. Furthermore, luciferase reporter activity and RIP assays confirmed that DLEUI could act as a competing endogenous RNA (ceRNA) for miR-421 that functioned as a tumor suppressor in glioma. Moreover, inhibition miR-421 partially restored the effect of DLEU1 knockdown on the glioma cells. DLEU1 could regulate myocyte enhancer factor 2D (MEF2D) expression, a known target of miR-421 in glioma cells. |
| Pubmed ID | 31360066 |
| Year | 2019 |
| Title | Long noncoding RNA DLEU1 aggravates glioma progression via the miR-421/MEF2D axis |
External Links
| Links for DLEU1 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |